
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7112663/publications.pdf Version: 2024-02-01



ARMANDO D'ANCELO

#	Article	IF	CITATIONS
1	Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, The, 1996, 348, 423-428.	6.3	1,270
2	Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon Journal of Clinical Investigation, 1987, 79, 918-925.	3.9	777
3	A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1. Journal of Thrombosis and Haemostasis, 2005, 3, 848-853.	1.9	534
4	Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery. New England Journal of Medicine, 1998, 339, 80-85.	13.9	522
5	Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry. American Journal of Medicine, 1996, 100, 530-536.	0.6	426
6	Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. Journal of Thrombosis and Haemostasis, 2014, 12, 2074-2088.	1.9	426
7	Homocysteine and Thrombotic Disease. Blood, 1997, 90, 1-11.	0.6	386
8	A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood, 2007, 110, 4144-4152.	0.6	246
9	Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Medicine, 1998, 24, 336-342.	3.9	241
10	A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. Thrombosis and Haemostasis, 2000, 84, 805-810.	1.8	208
11	Oral Anticoagulation Treatment in the Elderly. Archives of Internal Medicine, 2000, 160, 470.	4.3	119
12	Activation of Coagulation and Fibrinolysis during Coronary Surgery. Anesthesiology, 2001, 95, 1103-1109.	1.3	119
13	Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2012, 129, e177-e184.	0.8	119
14	Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Science Translational Medicine, 2015, 7, 277ra28.	5.8	118
15	Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis. Science Translational Medicine, 2018, 10, .	5.8	118
16	Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. Journal of Thrombosis and Haemostasis, 2006, 4, 2599-2606.	1.9	113
17	A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis, 2004, 2, 47-53.	1.9	112
18	Autoimmune Protein S Deficiency in a Boy with Severe Thromboembolic Disease. New England Journal of Medicine, 1993, 328, 1753-1757.	13.9	102

#	Article	IF	CITATIONS
19	Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation1. Transplantation, 2003, 75, 1296-1301.	0.5	98
20	The Role of Vitamin B12 in Fasting Hyperhomocysteinemia and Its Interaction with the Homozygous C677T Mutation of the Methylenetetrahydrofolate Reductase (MTHFR) Gene. Thrombosis and Haemostasis, 2000, 83, 563-570.	1.8	97
21	Evaluation of a New Rapid Quantitative D-dimer Assay in Patients with Clinically Suspected Deep Vein Thrombosis. Thrombosis and Haemostasis, 1996, 75, 412-416.	1.8	97
22	Fibrinolytic shutâ€down after surgery: impairment of the balance between tissueâ€ŧype plasminogen activator and its specific inhibitor. European Journal of Clinical Investigation, 1985, 15, 308-312.	1.7	92
23	Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood, 2012, 120, 4517-4520.	0.6	84
24	Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 83-91.	0.4	80
25	Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacological Research, 2017, 123, 146-156.	3.1	77
26	Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study. Thrombosis and Haemostasis, 1997, 78, 1438-1443.	1.8	77
27	Venous Thromboembolism in Acute Stroke. Archives of Neurology, 1992, 49, 279.	4.9	72
28	Effect of Clot-Detection Methods and Reagents on Activated Partial Thromboplastin Time (APTT): Implications in Heparin Monitoring by APTT American Journal of Clinical Pathology, 1990, 94, 297-306.	0.4	69
29	Intrasurgical plasmin enzyme in diabetic macular edema. American Journal of Ophthalmology, 2004, 138, 560-566.	1.7	67
30	Telomere Length in Peripheral Blood Mononuclear Cells Is Associated with Folate Status in Men ,. Journal of Nutrition, 2009, 139, 1273-1278.	1.3	66
31	Supportive management strategies for disseminated intravascular coagulation. Thrombosis and Haemostasis, 2016, 115, 896-904.	1.8	65
32	High-performance liquid chromatographic method for measuring total plasma homocysteine levels. Biomedical Applications, 1998, 719, 31-36.	1.7	62
33	Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography. PLoS ONE, 2015, 10, e0136463.	1.1	62
34	Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion. Thrombosis and Haemostasis, 1994, 72, 039-043.	1.8	62
35	Predictive Value of Plasma Thrombomodulin in Preeclampsia and Gestational Hypertension. Thrombosis and Haemostasis, 1998, 79, 1092-1095.	1.8	61
36	Relationship Between Homocysteine and Thrombotic Disease. American Journal of the Medical Sciences, 1998, 316, 129-141.	0.4	61

#	Article	IF	CITATIONS
37	CONGENITAL DEFICIENCY OF THROMBOXANE AND PROSTACYCLIN. Lancet, The, 1980, 315, 898-901.	6.3	60
38	Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood, 2002, 99, 526-530.	0.6	60
39	Tissue Factor and CCL2/Monocyte Chemoattractant Protein-1 Released by Human Islets Affect Islet Engraftment in Type 1 Diabetic Recipients. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5724-5728.	1.8	60
40	Hypercoagulability during l-asparaginase treatment: the effect of antithrombin III supplementation in vivo. British Journal of Haematology, 1990, 74, 465-470.	1.2	59
41	Comparison of Two Automated Coagulometers and the Manual Tilt-Tube Method for the Determination of Prothrombin Time. American Journal of Clinical Pathology, 1989, 92, 321-328.	0.4	56
42	Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Annals of Thoracic Surgery, 2001, 72, 470-475.	0.7	55
43	Liver gene therapy by lentiviral vectors reverses antiâ€factor <scp>IX</scp> preâ€existing immunity in haemophilic mice. EMBO Molecular Medicine, 2013, 5, 1684-1697.	3.3	55
44	Contribution of the Cystathionine β-Synthase Gene (844ins68) Polymorphism to the Risk of Early-onset Venous and Arterial Occlusive Disease and of Fasting Hyperhomocysteinemia. Thrombosis and Haemostasis, 2000, 84, 576-582.	1.8	54
45	An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. PLoS ONE, 2012, 7, e39484.	1.1	52
46	Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 2019, 144, 825-838.	1.5	50
47	Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ: British Medical Journal, 1994, 309, 239-240.	2.4	50
48	Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e19-e25.	0.8	48
49	Determining sulfur-containing amino acids by capillary electrophoresis: A fast novel method for total homocyst(e)ine human plasma. Electrophoresis, 1999, 20, 569-574.	1.3	46
50	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	1.0	44
51	MODERATE HYPERHOMOCYSTEINEMIA AND EARLY-ONSET CENTRAL RETINAL VEIN OCCLUSION. Retina, 2006, 26, 65-70.	1.0	43
52	Phosphorylcholine Coating May Limit Thrombin Formation During High-Risk Cardiac Surgery: A Randomized Controlled Trial. Annals of Thoracic Surgery, 2006, 81, 886-891.	0.7	42
53	Hyperhomocysteinemia and Thrombosis: Acquired Conditions. Thrombosis and Haemostasis, 1997, 78, 527-531.	1.8	41
54	The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	0.9	40

#	Article	IF	CITATIONS
55	Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. British Journal of Haematology, 1986, 63, 753-759.	1.2	39
56	Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 654-659.	1.1	39
57	Islet Transplantation Stabilizes Hemostatic Abnormalities and Cerebral Metabolism in Individuals With Type 1 Diabetes. Diabetes Care, 2014, 37, 267-276.	4.3	39
58	Anticoagulation Proteins C and S. , 1987, 214, 47-54.		36
59	Risk of Deep Vein Thrombosis Recurrence: High Negative Predictive Value of D-dimer Performed during Oral Anticoagulation. Thrombosis and Haemostasis, 2002, 88, 162-163.	1.8	34
60	No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thrombosis Research, 2002, 108, 127-131.	0.8	33
61	High Plasma Levels of Protein C Activity and Antigen in the Nephrotic Syndrome. Thrombosis and Haemostasis, 1986, 55, 031-033.	1.8	32
62	Thrombophilia, Homocystinuria, and Mutation of the Factor V Gene. New England Journal of Medicine, 1996, 335, 289-290.	13.9	32
63	Treatment of heparin-induced thrombocytopenia after cardiac surgery: Preliminary experience with fondaparinux. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 790-792.	0.4	31
64	Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica, 2002, 87, 1074-80.	1.7	30
65	L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation. Thrombosis Research, 1990, 59, 985-994.	0.8	29
66	Lowâ€grade endotoxemia and clotting activation in the early phase of pneumonia. Respirology, 2016, 21, 1465-1471.	1.3	29
67	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	1.0	29
68	Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 389-392.	1.3	28
69	Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome. Medicine (United States), 2018, 97, e12584.	0.4	28
70	Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica, 2002, 87, 1265-73.	1.7	28
71	The protein C pathway and sepsis. Thrombosis Research, 2012, 129, 296-300.	0.8	27
72	The Significance of Protein C Antigen in Acute and Chronic Liver Biliary Disease. American Journal of Clinical Pathology, 1985, 84, 454-458.	0.4	26

#	Article	IF	CITATIONS
73	Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: A case report. Thrombosis Research, 1995, 80, 327-331.	0.8	26
74	Determination of serum levels of complement component C4b-binding protein: influence of age and inflammation. International Journal of Clinical and Laboratory Research, 1992, 21, 171-175.	1.0	25
75	Intraoperative Moderate Acute Normovolemic Hemodilution Associated with a Comprehensive Blood-Sparing Protocol in Off-Pump Coronary Surgery. Anesthesia and Analgesia, 2004, 98, 1217-1223.	1.1	25
76	Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery. Intensive Care Medicine, 2009, 35, 1959-1963.	3.9	22
77	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. International Journal of Cardiology, 2017, 231, 143-149.	0.8	22
78	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. American Journal of Cardiovascular Drugs, 2020, 20, 61-71.	1.0	22
79	Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. Metabolism: Clinical and Experimental, 2021, 123, 154845.	1.5	22
80	Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays. Thrombosis Research, 1995, 77, 375-378.	0.8	20
81	Normalization of Multiple Hemostatic Abnormalities in Uremic Type 1 Diabetic Patients After Kidney-Pancreas Transplantation. Diabetes, 2004, 53, 2291-2300.	0.3	20
82	Prognostic significance of fibrinopeptide A in survivors of cerebral infarction Stroke, 1990, 21, 424-427.	1.0	18
83	Disseminated intravascular coagulation and severe peripheral neuropathy complicating ketoacidosis in a newly diagnosed diabetic child. Acta Diabetologica, 1994, 31, 173-174.	1.2	18
84	Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study. Blood Coagulation and Fibrinolysis, 2017, 28, 254-260.	0.5	18
85	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2019, 27, 403-405.	0.9	18
86	Diagnostic Value of Compression Ultrasonography and Fibrinogen-related Parameters for the Detection of Postoperative Deep Vein Thrombosis following Elective Hip Replacement: a Pilot Study. Thrombosis and Haemostasis, 1995, 74, 1235-1239.	1.8	18
87	Gene-Gene and Gene-Environment Interactions in Mild Hyperhomocysteinemia. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 337-341.	0.5	17
88	Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. British Journal of Haematology, 2005, 131, 100-108.	1.2	17
89	Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thrombosis and Haemostasis, 2006, 95, 573-575.	1.8	17
90	Thrombotic microangiopathy in pregnancy. Thrombosis Research, 2009, 123, S56-S62.	0.8	17

6

#	Article	IF	CITATIONS
91	PROTEIN C CONCENTRATE AS ADJUVANT TREATMENT IN NEONATES WITH SEPSIS-INDUCED COAGULOPATHY. Shock, 2010, 34, 341-345.	1.0	17
92	Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. Thrombosis Research, 2013, 132, 681-684.	0.8	16
93	Influence of Different Antithrombotic Regimens on Platelet-Mediated Thrombin Generation in Patients with Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, 415-422.	0.9	16
94	The Effect of Cigarette-Smoking on Cardiovascular Risk Factors: a Study of Monozygotic Twins Discordant for Smoking. Thrombosis and Haemostasis, 1996, 75, 014-018.	1.8	16
95	Primary antiphospholipid syndrome and neurologic events. Pediatric Neurology, 1993, 9, 473-475.	1.0	15
96	Soluble CD154 plasma levels in patients with systemic lupus erythematosus: Modulation by antiphospholipid antibodies. Arthritis and Rheumatism, 2004, 50, 1693-1694.	6.7	15
97	Vitreomacular traction syndrome: a comparison of treatment with intravitreal plasmin enzyme vs spontaneous vitreous separation without treatment. Eye, 2013, 27, 22-27.	1.1	15
98	High Levels of Circulating Thrombomodulin in Human Foetuses and Children. Thrombosis and Haemostasis, 1999, 81, 906-909.	1.8	15
99	Mild Hyperhomocysteinemia and Fibrinolytic Factors in Patients with History of Venous Thromboembolism. Thrombosis Research, 2000, 100, 271-278.	0.8	14
100	Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery. British Journal of Anaesthesia, 2007, 99, 349-352.	1.5	14
101	Protein S deficiency. Haematologica, 2008, 93, 498-501.	1.7	14
102	Genotype-independent in vivo oxidative stress following a methionine loading test: Maximal platelet activation in subjects with early-onset thrombosis. Thrombosis Research, 2011, 128, e43-e48.	0.8	14
103	Evaluation of Coagulometric Assays in the Assessment of Protein C Anticoagulant Activity; Variable Sensitivity of Commercial APTT Reagents to the Cofactor Effect of Protein S. Thrombosis and Haemostasis, 1989, 62, 861-867.	1.8	13
104	High dose antithrombin supplementation in early preeclampsia: A randomized, double blind, placebo-controlled study. Thrombosis Research, 2016, 140, 7-13.	0.8	13
105	Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assays (ELISA) for the Measurement of Vitamin K-Dependent Protein S: The Effect of Antibody Immunoreactivity on Plasma Protein S Antigen Determinations. Thrombosis and Haemostasis, 1992, 67, 631-638.	1.8	13
106	β-thromboglobulin and fibrinopeptide a in diabetes mellitus as markers of vascular damage. Acta Diabetologica Latina, 1985, 22, 39-45.	0.2	12
107	Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function. Journal of Thrombosis and Haemostasis, 2006, 4, 186-191.	1.9	12
108	Tranexamic acid for trauma. Lancet, The, 2010, 376, 1049-1050.	6.3	12

#	Article	IF	CITATIONS
109	Evidence and Clinical Judgment: Vena cava filters. Thrombosis and Haemostasis, 2014, 111, 618-624.	1.8	12
110	Protein S and protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo thrombin activity. Thrombosis Research, 1994, 75, 133-142.	0.8	11
111	Inherited deficiency of antithrombin III in an Italian kindred. Research in Clinic and Laboratory, 1980, 10, 521-531.	0.3	10
112	Total plasma homocysteine: influence of some common physiological variables. Amino Acids, 1993, 5, 17-21.	1.2	10
113	Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition. Haemophilia, 2019, 25, 685-692.	1.0	10
114	Chlorpropamide-alcohol flushing in non insulin-dependent diabetes: Prevalence of small and large vessel disease and of risk factors for angiopathy. Acta Diabetologica Latina, 1982, 19, 141-149.	0.2	9
115	Determination of Total Plasma Homocysteine: Comparison of a New Enzyme Immunoassay and a HPLC Method. Thrombosis and Haemostasis, 2000, 83, 968-969.	1.8	9
116	Membrane binding and anticoagulant properties of protein S natural variants. Thrombosis Research, 2010, 125, e33-e39.	0.8	9
117	Homocysteine and Thrombotic Disease. Blood, 1997, 90, 1-11.	0.6	9
118	Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity. Thrombosis Research, 1995, 80, 333-337.	0.8	8
119	Reply to â€^MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis'. European Journal of Human Genetics, 2002, 10, 579-582.	1.4	8
120	Moderate Hyperhomocysteinemia and Central Retinal Vein Occlusion. Thrombosis and Haemostasis, 2002, 87, 1078-1079.	1.8	7
121	Perioperative Management of a Heterozygous Carrier of Glanzmann???s Thrombasthenia Submitted to Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. Anesthesia and Analgesia, 2006, 103, 309-311.	1.1	7
122	Urinary excretion of iPF2α-III predicts the risk of future thrombotic events. A 10-year follow-up. Thrombosis Research, 2012, 129, 208-211.	0.8	7
123	Autoimmune Protein S Deficiency. New England Journal of Medicine, 1993, 329, 1898-1898.	13.9	6
124	A novel allele variant of the SERPINF2 gene responsible for severe plasmin inhibitor (α 2 -antiplasmin) deficiency in an Italian patient. Thrombosis Research, 2018, 166, 60-62.	0.8	6
125	Comment on 'increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos'. European Journal of Human Genetics, 2002, 10, 578-579.	1.4	5
126	Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline. Blood Coagulation and Fibrinolysis, 2018, 29, 562-566.	0.5	5

#	Article	IF	CITATIONS
127	Morphological and functional differences in haemostatic axis between kidney transplanted and end-stage renal disease patients. Transplant International, 2005, 18, 1036-1047.	0.8	4
128	Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?. European Journal of Cardio-thoracic Surgery, 2021, , .	0.6	4
129	Familial Protein S Deficiency Presenting as Deep Vein Thrombosis Occurring During Pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1990, 69, 537-539.	1.3	3
130	Safety of aprotinin (again). Lancet, The, 2008, 372, 27.	6.3	3
131	May restricted specificity of commercially available plasmin inhibitor activity assays affect correct diagnosis of antiplasmin deficiency?. Blood Coagulation and Fibrinolysis, 2019, 30, 52-53.	0.5	3
132	Thrombosis after Hypothermic Circulatory Arrest for Cardiovascular Surgery, Antifibrinolytic Drugs, and Thrombophilia. Anesthesiology, 2007, 106, 874-874.	1.3	3
133	Methionine Loading, Vitamin B_6 Status, and Premature Thromboembolic Disease. Annals of Internal Medicine, 1996, 125, 419.	2.0	3
134	Intrasurgical Plasmin Enzyme in Diabetic Macular Edema. American Journal of Ophthalmology, 2005, 139, 949.	1.7	2
135	Aprotinin and renal risk in cardiac surgery. Transfusion, 2006, 46, 2207-2207.	0.8	2
136	About the activation of the coagulation system during on-pump and off-pump coronary surgery and the use of antifibrinolytic drugs. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 733-734.	0.4	2
137	Complex Cardiac Surgery in Jehovah's Witnesses With Chronic Renal Failure. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 453-454.	0.6	2
138	Use of INR calibrator plasmas in the routine coagulation laboratory: A study of two thrombolastin reagents. Thrombosis Research, 2012, 130, e158-e162.	0.8	2
139	A Case of Branch Retinal Artery Occlusion following Orbital Cavernous Hemangioma Excision. European Journal of Ophthalmology, 2014, 24, 972-975.	0.7	2
140	Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?. Annals of Thoracic Surgery, 2018, 105, e47-e49.	0.7	2
141	Oral direct thrombin inhibition: a double-edged sword?. Heart, Lung and Vessels, 2015, 7, 191-7.	0.4	2
142	Poor vitamin B6 status: A novel potential thrombotic factor in chronic obstructive pulmonary disease. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, e17-e18.	1.1	1
143	Impaired dynamics of clot formation and hypofibrinolysis in severe sepsis are coexisting and strictly related. Intensive Care Medicine, 2016, 42, 622-623.	3.9	1
144	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Internal Medicine, 2020, 180, 332.	2.6	1

#	Article	IF	CITATIONS
145	Postoperative changes of protein C, a recently described inhibitor of blood coagulation. Research in Clinic and Laboratory, 1984, 14, 485-490.	0.3	1
146	A recombination event in the closely linked plasminogen and apolipoprotein(a) gene loci. Clinical Genetics, 1995, 47, 285-289.	1.0	0
147	Artificially depleted plasmas are not necessarily commutable with native patient plasmas for International Sensitivity Index calibration and International Normalized Ratio derivation: a rebuttal. Journal of Thrombosis and Haemostasis, 2012, 10, 1715-1716.	1.9	0
148	The SISET incorrectly cited the JAAM DIC scoring system. Thrombosis Research, 2012, 129, 661.	0.8	0
149	Hemostasis, Bleeding, Blood- sparing Strategies, and Allogeneic Transfusions in Thoraco-Abdominal Aortic Aneurysm Surgery. , 2011, , 287-297.		0